Search / Trial NCT06228937

Gut Microbiota in Patients With Limb Lymphedema and Recurrent Lymphangitis

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Jan 19, 2024

Trial Information

Current as of October 03, 2024

Recruiting

Keywords

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria (Group A):
  • * 18-85 years
  • * primary or secondary, upper or lower limb lymphedema, I-II-III stage ISL
  • * at least 3 episodes of soft tissue infection in an year, in the last 2 years
  • * consent to participate in the study
  • Inclusion Criteria (Group B):
  • * 18-85 years
  • * primary or secondary, upper or lower limb lymphedema, stage I-II-III (ISL)
  • * no episodes of soft tissue infection in the last 2 years
  • * consent to participate in the study
  • Exclusion Criteria:
  • * No compliance to perform limb compression and skin hygiene
  • * Antibiotic therapy in the last 15 days
  • * Diabetes mellitus
  • * Immunodeficiency
  • * Ongoing neoplastic pathology
  • * Taking immunosuppressive drugs
  • * Unavailability to follow-up for at least 24 months post-enrollment.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Rome, , Italy

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0